# Semaglutide market developments in Brazil and Spain

> Developing situation record from CLSTR: https://clstr.news/situations/semaglutide-market-developments-in-brazil-and-spain
> Updated: 2026-11-18T11:28:13.000Z. Sources: 2. Developments: 2.

Developments regarding semaglutide treatments have emerged in Brazil and Spain. In Brazil, Dr Reddy’s Laboratories secured marketing authorization from the National Health Surveillance Agency (ANVISA) to sell a generic version of the medication in 2 mg and 4 mg doses. This follows a previous regulatory denial in April. The company intends to launch the product in collaboration with Aché to target the Brazilian diabetes market.

In Spain, Novo Nordisk introduced a new 2 mg weekly dose of Ozempic. This dosage is funded by the Spanish National Health System for treating adults with type 2 diabetes. Medical specialists noted that the higher dose provides increased efficacy in glycemic control and weight management for patients who do not meet metabolic targets on the 1 mg dose.

## Timeline

### 2026-11-18: Novo Nordisk launches 2 mg Ozempic dose in Spain

A new 2 mg weekly dose of Ozempic is now available in Spain for adults with type 2 diabetes, offering improved glycemic control and weight reduction compared to the 1 mg dose.

2 sources. https://clstr.news/cluster/novo-nordisk-launches-2-mg-ozempic-dose-in-spain

### 2026-11-05: Dr Reddy’s Laboratories receives Brazil approval for generic Ozempic

Dr Reddy’s Laboratories has obtained regulatory approval from Brazil’s ANVISA to market a generic version of semaglutide for type 2 diabetes treatment.

5 sources. https://clstr.news/cluster/dr-reddys-laboratories-receives-brazil-approval-for-generic-ozempic

---
Cite as: Semaglutide market developments in Brazil and Spain. CLSTR, https://clstr.news/situations/semaglutide-market-developments-in-brazil-and-spain
